0001315863-25-000417.txt : 20250528 0001315863-25-000417.hdr.sgml : 20250528 20250528103013 ACCESSION NUMBER: 0001315863-25-000417 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(7) FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 EFFECTIVENESS DATE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioPharma Credit Investments V (Cayman) LP CENTRAL INDEX KEY: 0001780110 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-342354 FILM NUMBER: 25991822 BUSINESS ADDRESS: STREET 1: CO BIOPHARMA CREDIT INVESTMENTS V GP LLC STREET 2: CAYMAN CORPORATE CENTRE, 27 HOSPITAL RD CITY: GEORGE TOWN STATE: E9 ZIP: KY1-9008 BUSINESS PHONE: 212.883.2296 MAIL ADDRESS: STREET 1: CO BIOPHARMA CREDIT INVESTMENTS V GP LLC STREET 2: CAYMAN CORPORATE CENTRE, 27 HOSPITAL RD CITY: GEORGE TOWN STATE: E9 ZIP: KY1-9008 D/A 1 primary_doc.xml X0708 D/A LIVE 0001780110 BioPharma Credit Investments V (Cayman) LP CO BIOPHARMA CREDIT INVESTMENTS V GP LLC 190 ELGIN AVENUE GEORGE TOWN, GRAND CAYMAN E9 CAYMAN ISLANDS KY1-9008 212.883.2296 CAYMAN ISLANDS None None Other Cayman Islands Exempted Limited Partnership true N/A BioPharma Credit Investments V GP LLC c/o Walkers Corporate Limited 190 ELGIN AVENUE GEORGE TOWN, GRAND CAYMAN E9 CAYMAN ISLANDS KY1-9008 Director General Partner of the Issuer. Pooled Investment Fund Private Equity Fund false Decline to Disclose 06b 3C 3C.7 true 0001315863-24-000490 2019-06-27 true true true false 100000 Indefinite 10000000 Indefinite false 1 0 0 0 Interests in the Issuer are indirectly subject to incentive allocation and management fees, which are fully discussed in the Issuer's confidential offering documents, as well as fees and expenses related to the Board of Managers of the General Partner. false BioPharma Credit Investments V (Cayman) LP /s/ Nilani Perera Nilani Perera Manager of the General Partner for and on behalf of Issuer 2025-05-28